Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
Zuranolone for MDD is a newer, short 14-day oral treatment that works on the brain’s GABA system rather than serotonin, so it can reduce depressive symptoms within days and may help when standard antidepressants have not.
Your next steps include confirming the diagnosis, reviewing current meds and side effects, discussing candidacy, safety including driving precautions and potential costs with your clinician, and knowing when to seek urgent help, especially for suicidal thoughts or inability to care for yourself; there are several factors to consider. See below to understand more.
If you're still feeling depressed despite trying treatment, you're not alone. Major Depressive Disorder (MDD) can be persistent, exhausting, and difficult to treat. Many people try one or more antidepressants before finding relief. Recently, a newer option—zuranolone for MDD—has been approved and is changing how doctors think about depression treatment.
Here's what makes zuranolone different, who it may help, and what your next medical steps could look like.
Major Depressive Disorder is more than just feeling sad. It's a medical condition that affects how you think, feel, and function. Symptoms often include:
For a diagnosis of MDD, symptoms must last at least two weeks and interfere with daily life.
If you're experiencing several of these symptoms and want to understand whether they align with clinical depression, Ubie offers a free AI-powered Depression symptom checker that can help you identify patterns and prepare for a more informed conversation with your doctor.
Most commonly prescribed antidepressants—like SSRIs and SNRIs—work by increasing levels of serotonin or norepinephrine in the brain. While effective for many, they have limitations:
If you've tried at least one antidepressant without relief, that doesn't mean you're out of options. It simply means your treatment plan may need adjustment.
Zuranolone for MDD is a newer, FDA-approved oral medication designed specifically for adults with major depressive disorder.
What makes it unique?
This represents a significant shift in how depression can be treated.
Zuranolone is a neuroactive steroid that enhances the activity of GABA-A receptors in the brain.
GABA is a calming neurotransmitter. Think of it as the brain's "brake pedal." When GABA function is low or disrupted, mood regulation can suffer.
By strengthening GABA signaling, zuranolone may:
This mechanism is different from traditional antidepressants, which mainly focus on serotonin.
Clinical trials have shown that zuranolone for MDD may begin improving symptoms within 3 days, with meaningful improvement by 2 weeks.
That speed matters.
For people in significant distress, waiting 6–8 weeks for relief can feel unbearable. A faster-acting option may reduce suffering sooner and improve daily functioning more quickly.
However, it's important to understand:
Zuranolone for MDD may be appropriate for:
It is not automatically the right choice for everyone. Your medical history, current medications, and overall health all matter.
Like any medication, zuranolone can cause side effects. Reported ones include:
Because it can cause sleepiness and slowed reaction time:
It's important to tell your doctor about:
Your doctor will evaluate whether the benefits outweigh the risks in your situation.
No medication cures depression permanently.
MDD is often a recurring condition. Zuranolone treats an active depressive episode. Some patients may:
Depression management is often a long-term plan, not a one-time fix.
If you're still struggling, here's what you can do:
Make sure you truly have MDD and not another condition such as:
Accurate diagnosis is critical.
Ask:
Discuss:
Research consistently shows that combining medication with therapy (like cognitive behavioral therapy) improves outcomes.
These are not "quick fixes," but they matter:
Lifestyle changes support, but do not replace, medical treatment.
If you are experiencing:
This is urgent. Seek immediate medical help or contact emergency services. Depression can become life-threatening, and immediate care can save lives.
Do not wait for a medication change if your safety is at risk.
Here's the honest truth:
But it is a meaningful advancement.
A fast-acting, short-course oral medication that works through a different brain system offers hope—especially for people who have struggled with traditional antidepressants.
The key is having an informed, collaborative conversation with your doctor.
If you're still depressed, it doesn't mean you've failed treatment. It means your depression may require a different approach.
Zuranolone for MDD offers a new option—one that works differently and may act faster than older medications. For some people, that difference can be significant.
Start by understanding your symptoms. Use Ubie's free AI-powered Depression symptom checker to get personalized insights about what you're experiencing, then bring those results to a qualified healthcare professional.
Most importantly:
Depression is treatable. The path may not always be simple—but there are more options today than ever before.
(References)
* Kanes S, Colquhoun H, Gunduz-Bruce H, Sage J, Doherty J, Dresser K, Mendelson S, Jonas J, Zammit G, Ye S, Wessel T, Kuntz NL, Lasser R, Khurana D, Dawson GR. Zuranolone in patients with major depressive disorder: Results from the NEST clinical program. J Clin Psychiatry. 2023 Mar 1;84(2):22m14574. doi: 10.4088/JCP.22m14574. PMID: 36856553.
* Gunduz-Bruce H, Kanes S, Lasser R, Kuntz NL, Doherty J, Dresser K, Sage J, Zammit G, Ye S, Wessel T, Jonas J, Khurana D, Dawson GR. Zuranolone for Major Depressive Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2022 Dec;179(12):951-961. doi: 10.1176/appi.ajp.20220677. PMID: 36321422.
* Wessel T, Kuntz NL, Colquhoun H, Gunduz-Bruce H, Kanes S. Zuranolone for major depressive disorder. CNS Drugs. 2023 Apr;37(4):307-319. doi: 10.1007/s40263-023-00994-3. Epub 2023 Feb 15. PMID: 36790937.
* Mendelsohn S, Kanes S, Colquhoun H, Gunduz-Bruce H, Sage J, Doherty J, Dresser K, Wessel T, Kuntz NL, Dawson GR, Lasser R, Khurana D. Zuranolone for major depressive disorder: An overview of the Phase 3 clinical development program. Expert Rev Neurother. 2023 Apr;23(4):353-365. doi: 10.1080/14737175.2023.2163456. Epub 2023 Jan 26. PMID: 36592231.
* Kanes S, Colquhoun H, Gunduz-Bruce H, Lasser R, Doherty J, Dresser K, Sage J, Mendelson S, Jonas J, Ye S, Zammit G, Wessel T, Kuntz NL, Khurana D, Dawson GR. Zuranolone for Major Depressive Disorder: A Review of the Evidence. CNS Spectr. 2023 Oct;28(5):540-552. doi: 10.1017/S109285292300067X. Epub 2023 Oct 12. PMID: 37821101.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.